Colchicine: A New Dawn for Preventing Complications After Heart Attack? Unveiling its Network Pharmacology and the COLD-MI Trial
Arun HS Kumar1
- 1School of Veterinary Medicine, University College Dublin, Belfield, Dublin, IRELAND..
Received: 12-08-24; Revised: 17-08-2024; Accepted: 19-08-2024.
Volume 10, Issue 2 · pp. 27–32 · PUBLISHED · DOI: 10.5530/bems.10.2.7
ABSTRACT
Acute myocardial infarction, or heart attack, remains a significant cause of morbidity and mortality globally. Despite substantial advancements in acute management, the residual risk of recurrent coronary events, including myocardial infarction, stroke, and heart failure, poses a substantial challenge. This persistent threat underscores the imperative for ongoing research into novel therapeutic strategies to improve patient outcomes. The recently published COLD-MI trial results has generated significant interest by highlighting the potential of colchicine, a readily available and inexpensive medication, in preventing complications after a heart attack. This report delves into the rationale behind the COLD-MI trial, scrutinizes its findings, and explores the implications in correlation with network pharmacology of colchicine for future clinical practice
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Kumar, A. H. (). Colchicine: A New Dawn for Preventing Complications After Heart Attack? Unveiling its Network Pharmacology and the COLD-MI Trial. Biology, Engineering, Medicine and Science Reports, 10(2), 27–32. https://doi.org/10.5530/bems.10.2.7